NEW YORK (GenomeWeb News) – Cellectis and Genoway today announced a sublicensing deal covering Cellectis' homologous recombination technology.
The deal makes animal model firm Genoway the exclusive provider of the technology for research applications in genetically modified rodents. Cellectis retains rights to it for all other applications, such as bioproduction and therapeutics. Cellectis licenses the technology from Institut Pasteur.
The deal, the companies said, enables Genoway to provide academic and industry researchers with "complete secure access" to Cellectis' technology for use in rodent models.
"Access to this technology enables us to complete our portfolio of exclusive technologies and solutions to guarantee our customers that we'll provide them with a research model which exactly fits their needs," Genoway CEO Alexandre Fraichard said in a statement.
Financial and other terms of the agreement were not disclosed.